Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents

Abstract

BACKGROUND:To the best of the authors' knowledge, there has been relatively little research published to date regarding very longterm survivors of childhood and adolescent osteosarcoma. In the current study, the authors compared the very long-term survival outcomes of patients with osteosarcoma who were treated with either limb salvage procedures or amputation. METHODS: A total of 38 patients with osteosarcoma who survived 20 years from the time of diagnosis were divided into 2 groups according to whether they underwent amputation or limb salvage. Participants were asked to complete a questionnaire concerning their education, employment, annual income, marital status, health insurance, lifestyle, siblings, and all current and past health issues. RESULTS: Education, employment, marital status, and health insurance were not found to differ significantly between the 2 groups of survivors, who described themselves as being similar to their siblings. Eight percent of survivors underwent secondary amputation because of complications with an endoprosthesis. The cumulative incidence of second primary neoplasms was 13%, and this finding was significantly higher in females and in survivors who underwent radiotherapy and had a genetic predisposition. The second primary malignancies were breast cancer (ductal invasive carcinoma, ductal in situ carcinoma, and leiomyosarcoma), mediastinal leiomyosarcoma, and squamocellular carcinoma of the oral cavity and the uterine cervix. Amputees required more assistive walking support than survivors who received limb salvage treatment (P <.05, chi-square test). CONCLUSIONS: Despite the many challenges that osteosarcoma survivors face, patients who survived 20 years after their initial diagnosis reported having overall adjusted well to their physical limitations and were productive individuals.

SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition

“…Osteosarcoma is the most common histological form of primary bone tumors in children and adolescents which originates from the malignant transformation of mesenchymal cells with high mortality [1]. It often occurs during the differentiation of osteoid tissue and immature osteoblast.…”

“…Human SOX2 over lapping transcript (SOX2OT) gene can generate 8 lncRNA transcript variants (variant [1][2][3][4][5][6][7][8] which are functionally assumed to be correlated with cellular differentiation and carcinogenesis [12]. These variants show diverse expression profiles in different cell or tissue types [12].…”

Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells

“…Osteosarcoma (OS) is the most frequent primary solid malignancy of bone in children and adolescence (1,2). The current therapy regimen for high-grade OS includes induction by neoadjuvant chemotherapy followed by surgical resection (mostly limb-sparing or rarely amputation), adjuvant chemotherapy and radiotherapy (3).…”

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin

“…Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents (1,2). Although neoadjuvant chemotherapy followed by surgical excision has ameliorated the long-term survival of OS patients, most patients that do not respond to commonly used drugs, such as cisplatin and doxorubicin, have a poor prog nosis due to intrinsic or acquired drug resistance (3,4).…”